35 completed, 17 terminated, 13 recruiting, 10 unknown. 43 Phase 2, 33 Phase 1, 9 Not applicable, 6 Early Phase 1, 4 Phase 3.
Follow Phagocyte Bactericidal Dysfunction: new trials by email Literature Review of Phagocyte Bactericidal Dysfunction trials Research Report on Phagocyte Bactericidal Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lentiviral Gene Therapy for CGD Infusion of lentiviral TYF-CGD-modified autologous stem cells - Chronic Granulomatous Disease | Not applicable | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-07-01 | 2026-08-26 |
| Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department Haloperidol - Cannabinoid Hyperemesis Syndrome | Early Phase 1 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-11-01 | 2026-09-01 |
| Open-label Gene Therapy Study in p47-CGD SGX-001 - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Recruiting | Somagenetix AG | 5 | 2026-08-18 | 2026-09-17 |
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2025-09-10 | 2026-09-08 |
| Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease EN-374 - X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Active not recruiting | Ensoma | 15 | 2025-08-05 | 2026-08-21 |
| Skin Immunity Sample Collection Involving Blisters and Biopsies Blister induction, Skin Biopsies - Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD) | Early Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-12-09 | 2024-12-13 | |
| Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease Chronic Granulomatous Disease (CGD) | Recruiting | Ensoma | 60 | 2024-11-18 | 2026-08-17 | |
| A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) PM359 - Chronic Granulomatous Disease, Granulomatous Disease, Chronic | Phase 1 / Phase 2 | Enrolling by invitation | Prime Medicine, Inc. | 12 | 2024-10-17 | 2026-04-06 |
| pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47 - p47, Autosomal Recessive | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2024-06-25 | 2026-09-15 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells - Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2024-04-17 | 2026-08-13 |
| Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease Phagoburst, Lymphocytes subsets, Genetic testing - Chronic Granulomatous Disease | Unknown | National Institute for Mother and Child Health Alessandrescu Rusescu | 150 | 2023-11-01 | 2023-12-08 | |
| Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations Chronic Granulomatous Disease, Inflammatory Bowel Disease | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-09-08 | 2023-09-13 | ||
| Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD) Specimen Donation - Chronic Granulomatous Disease | Terminated | Sanguine Biosciences | 6 | 2023-05-23 | 2024-04-18 | |
| Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) JSP191 - Chronic Granulomatous Disease, CGD | Early Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 7 | 2023-01-02 | 2026-08-27 |
| Baby Detect : Genomic Newborn Screening Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1 | Completed | Centre Hospitalier Universitaire de Liege | 6824 | 2022-09-01 | 2025-08-12 | |
| Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications XELJANZ (tofacitinib) - Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2022-08-12 | 2026-05-07 |
| NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) gp91 Grans - Chronic Granulomatous Disease, Infection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2022-07-22 | 2026-10-02 |
| Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists Sirolimus, Cyclophosphamide, Alemtuzumab - Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2022-07-08 | 2026-10-13 |
| Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease Neocate Splash - Chronic Granulomatous Disease, Inflammatory Bowel Disease | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 3 | 2021-06-23 | 2025-12-11 |
Showing 20 of 93. Sign in to see all of them.
Granulomatous Disease, Chronic (78) · Chediak-Higashi Syndrome (16) · Wiskott-Aldrich Syndrome (14) · Lymphohistiocytosis, Hemophagocytic (13) · Immunologic Deficiency Syndromes (12) · Job Syndrome (12) · Anemia, Sickle Cell (10) · Severe Combined Immunodeficiency (10) · Anemia, Diamond-Blackfan (9) · Lymphoproliferative Disorders (9) · Infections (8) · Inflammatory Bowel Diseases (7) · Mucopolysaccharidosis I (7) · Common Variable Immunodeficiency (6) · Genetic Diseases, Inborn (6)
Hemic and Lymphatic Diseases (93) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (92) · Leukocyte Disorders (92) · Hematologic Diseases (90) · Immune System Diseases (88) · Genetic Diseases, Inborn (86) · Pathological Conditions, Signs and Symptoms (83) · Pathologic Processes (82) · Immunologic Deficiency Syndromes (81) · Disease Attributes (80) · Chronic Disease (78) · Genetic Diseases, X-Linked (78) · Primary Immunodeficiency Diseases (30) · Nutritional and Metabolic Diseases (21)
Busulfan (13) · Cyclophosphamide (11) · Alemtuzumab (7) · Stem Cell Transplantation (6) · fludarabine (6) · fludarabine phosphate (6) · Cyclosporine (5) · Sirolimus (5) · Melphalan (4) · Whole-Body Irradiation (4) · Antilymphocyte Serum (3) · Interferon-gamma (3) · plerixafor (3) · Etoposide (2) · Filgrastim (2)
National Institute of Allergy and Infectious Diseases (NIAID) (34) · Paul Szabolcs (4) · Masonic Cancer Center, University of Minnesota (3) · Children's Hospital Los Angeles (2) · Children's Hospital of Fudan University (2) · Emory University (2) · Ensoma (2) · Fairview University Medical Center (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Genethon (2) · National Cancer Institute (NCI) (2) · National Human Genome Research Institute (NHGRI) (2) · Shanghai Children's Medical Center (2) · University of Colorado, Denver (2) · Baylor College of Medicine (1)
United States (69) · United Kingdom (6) · China (4) · Canada (3) · Germany (3) · Russia (3) · France (2) · South Korea (2) · Switzerland (2) · Belgium (1) · Italy (1) · Netherlands (1) · Romania (1) · Spain (1)
Elizabeth M Kang, M.D. (9) · Paul Szabolcs, MD (4) · Christa S Zerbe, M.D. (3) · Suk S De Ravin, M.D. (3) · Angela Smith, MD (2) · Daniel R. Ambruso, MD (2) · Donald B. Kohn, MD (2) · Harry L Malech, M.D. (2) · John I Gallin, M.D. (2) · K. Scott Baker (2) · Adrian Thrasher, MD, PHD (1) · Adrian Thrasher, Professor (1) · Alexandra F Freeman, M.D. (1) · Alexandra Freeman, M.D. (1) · Alexandra Freeman, MD (1)
PMID 16582916, PMID 19965657, PMID 20004776, PMID 20489056, PMID 21772229, PMID 23818196, PMID 24139498, PMID 24290292, PMID 24331379, PMID 25075835, PMID 25239440, PMID 25459642, PMID 26095669, PMID 27262745, PMID 29664709, PMID 30720689, PMID 31315600, PMID 31376032, PMID 31599480, PMID 31745699, PMID 32634238, PMID 32750127, PMID 35113934, PMID 35142618, PMID 35699443, PMID 37042921, PMID 37562003, PMID 37659505, PMID 39413163, PMID 40178760, PMID 40920799, PMID 41358590, PMID 42061468, PMID 42606118
2015 (1), 2025 (1), P01HL073104 (1), U10HL069294 (1), U24CA076518 (1), U54AI082973 (1), UL1TR001082 (1)